• Type of Event: Earnings Call discussing Q2 and H1 FY27 unaudited financial results (Standalone and Consolidated).
  • Date and Time: Friday, November 06, 2026 at 05:00 P.M. IST.
  • Purpose: Discussion of quarterly results and strategic updates including acquisition developments.
  • Management Participants: Mr. Anand Desai (Managing Director), Mr. Gopal Agrawal (Chief Executive Officer), Mr. Amit Khurana (Chief Financial Officer), Ms. Hetvi Vyas (Deputy Chief Financial Officer), Mr. Vishal Thakkar (Advisor).
  • Availability of Materials: The transcript is available on the company's website at www.anupamrasayan.com with specific link: TranscriptofEarningsCallQ2FY-2026-27. Audio recordings were uploaded on stock exchanges on November 6, 2026, and will prevail in case of discrepancy.

Financial Highlights Disclosed

Q2 FY27 Performance (Consolidated):

  • Total Income: INR 821 crores (vs. INR 739 crores in Q2 FY26, +11% YoY)
  • EBITDA: INR 202 crores (vs. INR 144 crores in Q2 FY26, +41% YoY)
  • EBITDA Margin: 25% (vs. 19.4% in Q2 FY26)
  • PAT: INR 65 crores (vs. INR 57 crores in Q2 FY26, +14% YoY)
  • PAT Margin: 8%
  • Revenue Breakup: Life science-related specialty chemicals (42%), Performance Materials (28%), other fluorinated products (29%)

H1 FY27 Performance (Consolidated):

  • Total Income: INR 1,489 crores (vs. INR 1,230 crores in H1 FY26, +21% YoY)
  • EBITDA: INR 377 crores (vs. INR 273 crores in H1 FY26, +38% YoY)
  • EBITDA Margin: 25.5% (vs. 22.2% in H1 FY26)
  • PAT: INR 116 crores (vs. INR 106 crores in H1 FY26, +10% YoY)
  • PAT Margin: 7.9%
  • Revenue Breakup: Life science-related specialty chemical (41%), Performance Materials (29%), other fluorinated products (28%)

Key Strategic Developments:

  • Completed acquisition of Bliss GVS Pharma Limited on September 28, 2026 (Anupam now holds 50.07% equity)
  • Acquisition funded through INR 300 crores term loan and INR 1,450 crores raise through non-controlling, non-voting instrument from financial investors led by Bain Capital
  • Cumulative portfolio of LOIs and long-term contracts stands at approximately INR 17,496 crores
  • Signed six-year long-term supply agreement with leading U.S.-based global specialty metal manufacturer
  • CRISIL ESG rating improved to "Strong" at 62 (from "Adequate" 54 previously)
  • Working capital cycle reduced from 276 days to 271 days (excluding Bliss GVS balance sheet)
  • H1 FY27 operating cash flow was INR 328 crores (vs. previous full year's INR 334 crores)

Forward-looking Statements:

  • Management guided for H2 FY27 consolidated revenue of approximately INR 2,400-2,500 crores
  • Expects revenue cyclicality to reduce over next 4-8 quarters as Pharma and Performance Materials contribution increases
  • Targeting annualized run rate of around INR 4,800 crores
  • Expects organic growth of 20-25% over near-term 3-5 year period
  • Guided consolidated EBITDA margin of 22%-24% as steady state

Additional Notes Section

  • The document is a regulatory filing submitting the earnings call transcript to stock exchanges pursuant to Regulation 30 of SEBI LODR Regulations, 2015.
  • The transcript contains detailed financial data and strategic updates as presented during the earnings call.
  • Bliss GVS Pharma's balance sheet was consolidated as of September 2026, but revenue contribution was only for 3 days post-acquisition (from Sept 28, 2026).
  • The document includes a complete Q&A session with analysts covering various aspects of the business.